Increased Incidence of Blood Product Transfusions among Transplant Patients Treated with Linezolid Therapy: A Retrospective, Cohort Study

2015 ◽  
Vol 81 (11) ◽  
pp. 385-387
Author(s):  
Ashley J.P. Limkemann ◽  
Jeffrey M. Tessier ◽  
Leahna Cooney ◽  
Andrew Young ◽  
Thaddeus Puzio ◽  
...  
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Blood Product ◽  
Transplant Patients ◽  
Linezolid Therapy

scholarly journals 2789. Respiratory Syncytial Disease in Hospitalized Adults: A Retrospective Cohort Study

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S985-S986
Author(s):  
Hannah Nam ◽  
Michael G Ison
Keyword(s):  
Mechanical Ventilation ◽  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Severe Disease ◽  
Solid Organ ◽  
Cell Transplant ◽  
Immunocompromised Patients ◽  
Transplant Patients ◽  
History Of

Abstract Background Respiratory syncytial virus (RSV) is associated with significant mortality rates amongst hematopoietic stem cell transplant (HSCT) and lung transplant recipients. Although RSV is responsible for ~177,000 hospitalizations and 14,000 deaths annually, few epidemiologic studies including all adults including those with immunocompromise have been conducted over multiple seasons. Methods A retrospective cohort study of adults admitted to a large academic medical center in Chicago, IL from 2009 to 2018 was conducted in patients with positive RSV PCR. Specific data on clinical presentation, management, and outcomes were collected by manual chart review. Descriptive statistics were calculated, and Pearson’s Chi-Squared test was utilized to assess association between severe disease status and comorbidities. Results A total of 140 patients* were admitted during part of the study period (2016–2018) with positive PCR for RSV. Most patients had otherwise underlying comorbidities prior to admission (lung 44.2%, heart 40.0%, diabetes 20.7%), history of immunocompromise (36.4%, 51) or history of smoking (39.2%, 55). Cough was the most common symptom among all hospitalized adults (90.7%, 127). However, patients with a history of transplant (both HSCT and SOT) more commonly displayed symptoms of fevers at presentation (50%, 10) when compared with non-immunocompromised patients (36.6%, 36). ICU admission occurred in one-third of the hospitalized patients, with no significant difference amongst transplant patients, immunocompromised patients, and non-immunocompromised patients. Need for mechanical ventilation was highest in patients with co-infections. None of the co-morbidities measured were independent risk factors for severe disease. Most patients (78.5%, 110) were discharged home. Among the 12 fatal cases, all were admitted to the ICU with seven (58.3%) requiring mechanical ventilation. Three (25.0%) were immunocompromised while two (16.7%) were HSCT patients, but none were solid-organ transplant patients. *Ongoing data collection. Conclusion RSV patients were diverse in their demographics, treatment, and outcomes. Large percentages of patients had underlying comorbidities such as immunocompromise due to HSCT, lung and heart disease. Disclosures All authors: No reported disclosures.

Impaired cardiac autonomic response in lung transplant patients: A retrospective cohort study

2019 ◽  
Vol 33 (7) ◽  
Author(s):  
Vanessa Martelli ◽  
Sunita Mathur ◽  
Lisa Wickerson ◽  
Chaya Gottesman ◽  
Denise Helm ◽  
...  
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Lung Transplant ◽  
Autonomic Response ◽  
Transplant Patients

scholarly journals Characteristics of Epstein-Barr viraemia in adult liver transplant patients: A retrospective cohort study

2014 ◽  
Vol 27 (8) ◽  
pp. 838-846 ◽  
Author(s):  
Neil Halliday ◽  
Colette Smith ◽  
Claire Atkinson ◽  
James O'Beirne ◽  
David Patch ◽  
...  
Keyword(s):  
Cohort Study ◽  
Liver Transplant ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Adult Liver ◽  
Transplant Patients ◽  
Epstein Barr

scholarly journals Flucloxacillin decreases tacrolimus blood trough levels: a single-center retrospective cohort study

2020 ◽  
Vol 76 (12) ◽  
pp. 1667-1673
Author(s):  
Herman Veenhof ◽  
Hugo M. Schouw ◽  
Martine T. P. Besouw ◽  
Daan J. Touw ◽  
Valentina Gracchi
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Case Reports ◽  
Rank Test ◽  
Single Center ◽  
Transplant Patients ◽  
Signed Rank ◽  
Signed Rank Test ◽  
Trough Levels

Abstract Purpose Tacrolimus and everolimus are widely used to prevent allograft rejection. Both are metabolized by the hepatic cytochrome P450 (CYP) enzyme CYP3A4 and are substrate for P-glycoprotein (P-gp). Drugs influencing the activity or expression of CYP enzymes and P-gp can cause clinically relevant changes in the metabolism of immunosuppressants. Several case reports have reported that flucloxacillin appeared to decrease levels of drugs metabolized by CYP3A4 and P-gp. The magnitude of this decrease has not been reported yet. Methods In this single-center retrospective cohort study, we compared the tacrolimus and everolimus blood trough levels (corrected for the dose) before, during, and after flucloxacillin treatment in eleven transplant patients (tacrolimus n = 11 patients, everolimus n = 1 patient, flucloxacillin n = 11 patients). Results The median tacrolimus blood trough level decreased by 37.5% (interquartile range, IQR 26.4–49.7%) during flucloxacillin treatment. After discontinuation of flucloxacillin, the tacrolimus blood trough levels increased by a median of 33.7% (IQR 22.5–51.4%). A Wilcoxon signed-rank test showed statistically significantly lower tacrolimus trough levels during treatment with flucloxacillin compared with before (p = 0.009) and after flucloxacillin treatment (p = 0.010). In the only available case with concomitant everolimus and flucloxacillin treatment, the same pattern was observed. Conclusions Flucloxacillin decreases tacrolimus trough levels, possibly through a CYP3A4 and/or P-gp-inducing effect. It is strongly recommended to closely monitor tacrolimus and everolimus trough levels during flucloxacillin treatment and up to 2 weeks after discontinuation of flucloxacillin.

scholarly journals Retrospective Cohort Study: Ledipasvir-Sofosbuvir With/Without Ribavirin for Chronic Hepatitis C Post–Liver Transplant in a Real-World Population

2018 ◽  
Vol 34 (5) ◽  
pp. 199-203
Author(s):  
Kelsey L. Hawkins ◽  
Ives Hot
Keyword(s):  
Cohort Study ◽  
Hepatitis C ◽  
Liver Transplant ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Medical Center ◽  
Academic Medical Center ◽  
The United States ◽  
World Population ◽  
Transplant Patients

Background: Liver damage caused by hepatitis C virus (HCV) is the number one indication for liver transplantation in the United States and Europe. Patients with a detectable HCV level at time of transplant will universally develop a recurrent infection, which can lead to increased morbidity and mortality. Objective: To assess the sustained virologic response rate post end-of-treatment (SVR) in HCV-infected, post–liver transplant patients at the University of Washington Medical Center (UWMC) treated with ledipasvir-sofosbuvir (LDV/SOF). Methods: This retrospective, cohort study of HCV-positive, genotype 1 or 4 infected, post–liver transplant patients treated with LDV/SOF was conducted at a large academic medical center affiliated clinic. Patients treated with 12 weeks of LDV/SOF with or without ribavirin were included in the 12-week group, and patients treated with 24 weeks of LDV/SOF without ribavirin were included in the 24-week group. Results: Twenty-nine patients with recurrent HCV post–liver transplant receiving 12 weeks of LDV/SOF with or without ribavirin and 32 patients receiving 24 weeks of LDV/SOF alone were assessed. SVR was achieved by 100% (29/29) of patients in the 12-week group and 100% (32/32) of patients in the 24-week group. Conclusion: Post–liver transplant patients at UWMC treated with LDV/SOF for recurrent HCV achieved high rates of SVR.

Sign in / Sign up

Export Citation Format

Share Document